Nouha Ben Othman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nouha Ben Othman has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Olivier Gérard
Department of Clinical Pharmacology Université Côte d'Azur, University Hospital Centre of Nice Nice France
3 shared publications - Milou-Daniel Drici
Department of Clinical Pharmacology, Université Côte d’Azur, University Hospital Centre of Nice, Nice, France
3 shared publications - Diane Merino
Department of Psychiatry, University Hospital of Nice, 06000 Nice, France
2 shared publications Fanny Rocher
Department of Clinical Pharmacology Université Côte d'Azur, University Hospital Centre of Nice Nice France
2 shared publications- Fanny Rocher
University Hospital of Nice Department of Clinical Pharmacology and Pharmacovigilance Center of Nice , Nice
2 shared publications - Arnaud Fernandez
Affiliations Suicidology and Consultation-Liaison Psychiatry Unit, University Department of Child and Adolescent Psychiatry, University Pediatric Hospital–Lenval, Nice, France, Université Côte d’Azur, Cognition Behaviour Technology (CoBTeK) Laboratory, Nice Cedex, France, Regional Center for Psychotrauma (CRP), Nice—PACA, Corsica, France
1 shared publication
Latest Publications
- Open Access
- 21 September 2026
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (5) , e70323
Drug‐Induced Liver Injury During Treatment With Tocilizumab: A Case Report of an Atypical Pattern Lesion
Tocilizumab is an interleukin‐6 (IL‐6) receptor antagonist indicated for various rheumatologic conditions. While hepatotoxicity is a recognized adverse effect, it predominantly manifests as hepatocellular injury. We report a rare case of drug‐induced liver injury (DILI) presenting with a cholestatic pattern and cholangitis features in a 75‐year‐old patient treated for giant cell arteritis. Following the third tocilizumab infusion, the patient developed jaundice and abdominal pain. Laboratory investigations revealed a cholestatic pattern of liver injury (ALT/ALP ( R ) ratio ≤ 2) with marked cholestasis. Imaging findings raised suspicion for cholangitis. After ruling out infectious, autoimmune, and metabolic aetiologies, a liver biopsy confirmed neutrophilic cholangitis and marked intrahepatic and sinusoidal cholestasis. Drug discontinuation, along with ursodeoxycholic acid treatment, led to clinical and biochemical resolution. This case is notable as tocilizumab‐induced liver injury rarely presents with cholangitic features. The pathophysiology may involve the disruption of IL‐6 signaling, which plays a pivotal role in maintaining biliary epithelial integrity. Clinicians should be vigilant for this atypical cholestatic presentation to ensure prompt drug withdrawal.
- 21 September 2026
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (5) , e70323
Open AccessDrug‐Induced Liver Injury During Treatment With Tocilizumab: A Case Report of an Atypical Pattern Lesion
Tocilizumab is an interleukin‐6 (IL‐6) receptor antagonist indicated for various rheumatologic conditions. While hepatotoxicity is a recognized adverse effect, it predominantly manifests as hepatocellular injury. We report a rare case of drug‐induced liver injury (DILI) presenting with a cholestatic pattern and cholangitis features in a 75‐year‐old patient treated for giant cell arteritis. Following the third tocilizumab infusion, the patient developed jaundice and abdominal pain. Laboratory investigations revealed a cholestatic pattern of liver injury (ALT/ALP ( R ) ratio ≤ 2) with marked cholestasis. Imaging findings raised suspicion for cholangitis. After ruling out infectious, autoimmune, and metabolic aetiologies, a liver biopsy confirmed neutrophilic cholangitis and marked intrahepatic and sinusoidal cholestasis. Drug discontinuation, along with ursodeoxycholic acid treatment, led to clinical and biochemical resolution. This case is notable as tocilizumab‐induced liver injury rarely presents with cholangitic features. The pathophysiology may involve the disruption of IL‐6 signaling, which plays a pivotal role in maintaining biliary epithelial integrity. Clinicians should be vigilant for this atypical cholestatic presentation to ensure prompt drug withdrawal.
- Open Access
- 7 September 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
Mental health safety profile of CFTR modulators in pediatrics and adults: insights from the French pharmacovigilance database and from VigiBase
Rationale: CFTR modulators (CFTRms) have transformed cystic fibrosis care, yet concern exists regarding their mental health safety profile. Objective: To provide further information, we conducted an analysis of CFTRm-related mental health disorders using two spontaneous pharmacovigilance reporting databases in real-world settings. Methods: We analyzed reports from the French Pharmacovigilance Database (FPD) and VigiBase, the WHO global individual case safety reports database. Reports recorded between 2012 and 2024 involving any CFTRm and psychiatric disorders were included. In VigiBase, we conducted a case-non case, disproportionality analysis using the Reporting Odds Ratio (ROR), overall and stratified by age group (pediatrics vs. adults) and by CFTRm type. This study was conducted in accordance with the STROBE and the READUS-PV guidelines. Results: In the FPD, 116 cases were analyzed. ELX/TEZ/IVA was suspected in 98% of cases and no single case was reported with ivacaftor alone. Sleep (61%), mood (37%), and anxiety disorders (27%) were the most frequently reported, with suicidal behaviors being infrequent, including 6 suicide attempts and no completed suicide. In VigiBase (n = 3,407), sleep disorders predominated in children, whereas mood and suicidality disorders were most frequent in adolescents. The median time to onset was 60 days (Q1-Q3: 12—150 days). Mental health disorders were disproportionately reported with CFTRms, particularly ELX/TEZ/IVA, while they were not with other combination therapies, compared to other drugs in the database. Disproportionality signals were slightly stronger in pediatrics than in adults. Conclusions: CFTRms, especially ELX/TEZ/IVA, are associated with increased reporting of mental health disorders, predominantly sleep and mood disorders. Pediatrics appear to be particularly affected. Prospective observational studies are warranted to confirm these findings and elucidate underlying pathophysiological mechanisms. Registration: OSF: mfyx3
- 7 September 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
Open AccessMental health safety profile of CFTR modulators in pediatrics and adults: insights from the French pharmacovigilance database and from VigiBase
Rationale: CFTR modulators (CFTRms) have transformed cystic fibrosis care, yet concern exists regarding their mental health safety profile. Objective: To provide further information, we conducted an analysis of CFTRm-related mental health disorders using two spontaneous pharmacovigilance reporting databases in real-world settings. Methods: We analyzed reports from the French Pharmacovigilance Database (FPD) and VigiBase, the WHO global individual case safety reports database. Reports recorded between 2012 and 2024 involving any CFTRm and psychiatric disorders were included. In VigiBase, we conducted a case-non case, disproportionality analysis using the Reporting Odds Ratio (ROR), overall and stratified by age group (pediatrics vs. adults) and by CFTRm type. This study was conducted in accordance with the STROBE and the READUS-PV guidelines. Results: In the FPD, 116 cases were analyzed. ELX/TEZ/IVA was suspected in 98% of cases and no single case was reported with ivacaftor alone. Sleep (61%), mood (37%), and anxiety disorders (27%) were the most frequently reported, with suicidal behaviors being infrequent, including 6 suicide attempts and no completed suicide. In VigiBase (n = 3,407), sleep disorders predominated in children, whereas mood and suicidality disorders were most frequent in adolescents. The median time to onset was 60 days (Q1-Q3: 12—150 days). Mental health disorders were disproportionately reported with CFTRms, particularly ELX/TEZ/IVA, while they were not with other combination therapies, compared to other drugs in the database. Disproportionality signals were slightly stronger in pediatrics than in adults. Conclusions: CFTRms, especially ELX/TEZ/IVA, are associated with increased reporting of mental health disorders, predominantly sleep and mood disorders. Pediatrics appear to be particularly affected. Prospective observational studies are warranted to confirm these findings and elucidate underlying pathophysiological mechanisms. Registration: OSF: mfyx3
- Open Access
- 23 October 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 168 (3) , 958-964
Lipschütz ulcer following first dose of COVID ‐19 tozinameran vaccine: Report of a case and review of a World Health Organization pharmacovigilance database
Lipschütz ulcer (LU) is a condition known for painful vulvar ulcers, typically affecting young women and often linked to infectious agents. Recent reports have indicated a potential connection between LU and COVID‐19 vaccination, particularly after the second or booster doses. This study presents a case of LU following the first dose of tozinameran in a young woman who had a previous SARS‐CoV‐2 infection and investigates similar cases globally. An 18‐year‐old woman experienced vulvar pain and ulcers 2‐days after her initial COVID‐19 vaccine dose. After ruling out infections through serological tests, a diagnosis of LU was made, and her symptoms resolved after 10 days. A literature search and VigiBase® analysis revealed 11 cases of LU following COVID‐19 vaccination, and 519 vulvovaginal ulcer cases associated with these vaccines were identified in Vigibase®, with a median onset of 2 days. Most LU cases occurred after the second dose or booster shots. The primary hypothesis for this association is a type 3 hypersensitivity reaction mediated by immune complexes, possibly triggered by prior exposure, as many cases occurred after the second dose. Interestingly, the presented case suggests that prior COVID‐19 infection could serve as sensitization. In conclusion, this study highlights the potential occurrence of LU after the initial COVID‐19 vaccine dose in young patients with prior COVID‐19 infection. While the risk of recurrence after subsequent vaccinations or infections remains uncertain, the benefits of vaccination outweigh the risks. Clinicians and patients should be aware of this potential issue to make informed decisions regarding vaccination.
- 23 October 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 168 (3) , 958-964
Open AccessLipschütz ulcer following first dose of COVID ‐19 tozinameran vaccine: Report of a case and review of a World Health Organization pharmacovigilance database
Lipschütz ulcer (LU) is a condition known for painful vulvar ulcers, typically affecting young women and often linked to infectious agents. Recent reports have indicated a potential connection between LU and COVID‐19 vaccination, particularly after the second or booster doses. This study presents a case of LU following the first dose of tozinameran in a young woman who had a previous SARS‐CoV‐2 infection and investigates similar cases globally. An 18‐year‐old woman experienced vulvar pain and ulcers 2‐days after her initial COVID‐19 vaccine dose. After ruling out infections through serological tests, a diagnosis of LU was made, and her symptoms resolved after 10 days. A literature search and VigiBase® analysis revealed 11 cases of LU following COVID‐19 vaccination, and 519 vulvovaginal ulcer cases associated with these vaccines were identified in Vigibase®, with a median onset of 2 days. Most LU cases occurred after the second dose or booster shots. The primary hypothesis for this association is a type 3 hypersensitivity reaction mediated by immune complexes, possibly triggered by prior exposure, as many cases occurred after the second dose. Interestingly, the presented case suggests that prior COVID‐19 infection could serve as sensitization. In conclusion, this study highlights the potential occurrence of LU after the initial COVID‐19 vaccine dose in young patients with prior COVID‐19 infection. While the risk of recurrence after subsequent vaccinations or infections remains uncertain, the benefits of vaccination outweigh the risks. Clinicians and patients should be aware of this potential issue to make informed decisions regarding vaccination.
- 4 May 2022
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Protocol: Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review
Review question / Objective: In children and youth treated with olanzapine, clozapine, or loxapine and having undergone genotyping, which are the pharmacogenetic variants underlying the antipsychotics' adverse drug reactions and efficacy? What are the most frequently investigated adverse drug reactions and variants ? What is described about the specific effect of CYP1A2 variants ? Therefore, we aimed to review the pharmacogenetic variants underlying olanzapine, clozapine and loxapine ADRs and/or efficacy, in children and youth having undergone genotyping. Then, assessed the most frequently investigated ADRs and genetic polymorphisms in this population. Finally, we investigated the specific effect of CYP1A2 variants in the occurrence of ADRs and/or lack of therapeutic effect. Condition being studied: This review focuses on children, adolescents and youth treated with antipsychotics (olanzapine, clozapine, loxapine) and experienced adverse drug reactions.
- 4 May 2022
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Protocol: Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review
Review question / Objective: In children and youth treated with olanzapine, clozapine, or loxapine and having undergone genotyping, which are the pharmacogenetic variants underlying the antipsychotics' adverse drug reactions and efficacy? What are the most frequently investigated adverse drug reactions and variants ? What is described about the specific effect of CYP1A2 variants ? Therefore, we aimed to review the pharmacogenetic variants underlying olanzapine, clozapine and loxapine ADRs and/or efficacy, in children and youth having undergone genotyping. Then, assessed the most frequently investigated ADRs and genetic polymorphisms in this population. Finally, we investigated the specific effect of CYP1A2 variants in the occurrence of ADRs and/or lack of therapeutic effect. Condition being studied: This review focuses on children, adolescents and youth treated with antipsychotics (olanzapine, clozapine, loxapine) and experienced adverse drug reactions.